Short-Term Psychodynamic Psychotherapy and Fluoxetine in Major Depressive Disorder: A Randomized Comparative StudySalminen J.K.b, c · Karlsson H.a · Hietala J.d · Kajander J.e · Aalto S.f · Markkula J.d · Rasi-Hakala H.g · Toikka T.c
aDepartment of Psychiatry, University of Helsinki, Helsinki; bDepartment of Health and Functional Capacity, Laboratory for Population Research, National Public Health Institute, cResearch Department of the Social Insurance Institution, dDepartment of Psychiatry, University of Turku, eTurku PET Center, fDepartment of Psychology, Åbo Akademi University, and gPsykiatrian erikoislääkärit, Turku, Finland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: There are few studies comparing the efficacy of short-term psychodynamic psychotherapy (STPP) and pharmacotherapy in major depressive disorder. We conducted a comparative study on the efficacy of STPP versus fluoxetine treatment in patients with major depressive disorder in a primary care setting. Methods: Fifty-one patients with major depressive disorder (DSM-IV) of mild or moderate severity were recruited through occupational health services providing primary health care. Patients were randomized to receive either STPP (1 session/week) or fluoxetine treatment (20–40 mg/day) for 16 weeks. The outcome measures included the Hamilton Depression Rating Scale (HDRS), the Beck Depression Inventory (BDI), and the Social and Occupational Functioning Assessment Scale (SOFAS). Results: Intent-to-treat analyses indicated that both treatments were highly effective in reducing the HDRS (p < 0.0001) and BDI (p < 0.0001) scores, as well as in improving functional ability (SOFAS; p < 0.0001), with no statistically significant differences between the treatments. Of those 40 subjects who completed the follow-up, 57% in the psychotherapy group and 68% in the fluoxetine group showed full remission (HDRS ≤7) after 4 months. Conclusions: Both STPP and pharmacological treatment with fluoxetine are effective in reducing symptoms and in improving functional ability of primary care patients with mild or moderate depression. This study suggests no marked differences in the therapeutic effects of these two treatment forms in a primary care setting.
© 2008 S. Karger AG, Basel
- Svartberg M, Stiles TC: Comparative effects of short-term psychodynamic psychotherapy: a meta-analysis. J Consult Clin Psychol 1991;59:704–714.
- Crits-Christoph P: The efficacy of brief dynamic psychotherapy: a meta-analysis. Am J Psychiatry 1992;149:151–158.
- Anderson EM, Lambert MJ: Short-term dynamically oriented psychotherapy: a review and meta-analysis. Clin Psychol Rev 1995;15:503–514.
- Leichsenring F: Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in depression: a meta-analytic approach. Clin Psychol Rev 2001;21:401–419.
- Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, Wessely S: A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess 2001;5:1–173.
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders. Arch Gen Psychiatry 2004;61:1209–1216.
- Stark P, Hardison CD: A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53–58.
- Feighner JP, Boyer WF, Merideth CH, et al: A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989;4:127–134.
- Bech P, Cialdella P, Haugh MC, et al: Meta-analysis of randomised controlled trials of fluoxetine v placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000;176:421–428.
First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician Version. Washington, American Psychiatric Press, 1997.
- Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296.
Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:53–63.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
Tilastokeskus: The Classification of Socio-Economic Groups. Handbook of the Central Statistical Office of Finland (in Finnish with an English summary). Helsinki, Tilastokeskus, 1989.
Mann J: Time-Limited Psychotherapy. Cambridge, Harvard University Press, 1973.
Malan DH: The Frontier of Brief Psychotherapy. New York, Plenum, 1976.
- Posternak MA, Miller I: Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. J Affect Disord 2001;66:139–146.
- DeRubeis RJ, Hollon SD, Amsterdam JD, et al: Cognitive therapy versus medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62:409–416.
- Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D: Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995;310:441–445.
- Jarrett RB, Rush AJ: Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry 1994;57:115–132.
- Bond M: Psychodynamic psychotherapy in the treatment of mood disorders. Curr Opin Psychiatry 2006;19:40–43.
- Fava M, Rush AJ: Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139–153.
- Maina G, Rosso G, Crespi C, Bogetto F: Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study. Psychother Psychosom 2007;76:298–305.
- Blom MBJ, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, van Dyck R: Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom 2007;76:289–297.
- Murray CJL, Lopez AD: Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–1442.
- Salminen JK, Saarijärvi S, Raitasalo R: Depression and disability pension in Finland. Acta Psychiatr Scand 1997;95:242–243.
- Isometsä ET, Katila H, Aro T: Disability pension for major depression in Finland. Am J Psychiatry 2000;157:1869–1872.
Järvisalo J, Raitasalo R, Salminen JK, Klaukka T, Kinnunen E: Depression and other mental disorders, sickness absenteeism and work disability pensions in Finland; in Järvisalo J, Andersson B, Boedeker W, Houtman I (eds): Mental Disorders as a Major Challenge in Prevention of Work Disability. Experiences in Finland, Germany, the Netherlands and Sweden.Social Security and Health Reports 66. Helsinki, Kela, 2005, pp 27–59.
- Post RM: Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999–1010.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.